This company listing is no longer active
23N Stock Overview
Nuvo Pharmaceuticals Inc., doing business as Miravo Healthcare, provides prescription and non-prescription products for pain, allergy, neurology, and dermatology worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Nuvo Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.90 |
| 52 Week High | CA$1.10 |
| 52 Week Low | CA$0.34 |
| Beta | 0.78 |
| 1 Month Change | -0.55% |
| 3 Month Change | 109.30% |
| 1 Year Change | -3.23% |
| 3 Year Change | 97.37% |
| 5 Year Change | n/a |
| Change since IPO | -94.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| 23N | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -0.6% | 2.5% | 1.8% |
| 1Y | -3.2% | -27.7% | 2.2% |
Return vs Industry: 23N exceeded the German Pharmaceuticals industry which returned -8.9% over the past year.
Return vs Market: 23N exceeded the German Market which returned -13.7% over the past year.
Price Volatility
| 23N volatility | |
|---|---|
| 23N Average Weekly Movement | 30.2% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 23N's share price has been volatile over the past 3 months.
Volatility Over Time: 23N's weekly volatility has increased from 23% to 30% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 101 | Jesse Ledger | www.miravohealthcare.com |
Nuvo Pharmaceuticals Inc., doing business as Miravo Healthcare, provides prescription and non-prescription products for pain, allergy, neurology, and dermatology worldwide. The company operates in three segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. It offers Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria; Cambia, a nonsteroidal anti-inflammatory drug for migraine; Suvexx/Treximet, a migraine medicine; NeoVisc, an injectable viscosupplement for osteoarthritis; and Resultz, FullMarks, and LAUSBUB for head lice infestations.
Nuvo Pharmaceuticals Inc. Fundamentals Summary
| 23N fundamental statistics | |
|---|---|
| Market cap | €10.56m |
| Earnings (TTM) | €10.42m |
| Revenue (TTM) | €49.72m |
1.0x
P/E Ratio0.2x
P/S RatioIs 23N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 23N income statement (TTM) | |
|---|---|
| Revenue | CA$72.42m |
| Cost of Revenue | CA$27.36m |
| Gross Profit | CA$45.06m |
| Other Expenses | CA$29.89m |
| Earnings | CA$15.17m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.33 |
| Gross Margin | 62.22% |
| Net Profit Margin | 20.95% |
| Debt/Equity Ratio | 1,149.7% |
How did 23N perform over the long term?
See historical performance and comparison